For the second year, Exact Sciences earns a place in Deloitte’s Technology Fast 500, an annual list of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. The Technology Fast 500 is based on percentage of revenue growth from fiscal year 2013 to 2016. Exact Sciences ranked 68 on the list of a total 500 companies.
Cologuard orders generate more than just a colon cancer screening test. The process that supports each test is a system that includes not only the “hardware” needed to provide your sample for screening, but all the information and support needed to ensure every patient can complete the test, receive timely results from their ordering provider, and stay informed every step of the way. We call this our Patient Compliance Program – it results in more patients complying, or following through on their intent to get screened for colon cancer – and it’s proven to be essential to the impact Cologuard is having on getting more people screened.
World-class lab and office space to support demand for Cologuard
- Exact Sciences selects 650 Forward Drive in Madison as site for expanded lab; company also takes ownership of existing office building on site, renamed 1 Exact Lane.
- Campus offers potential to accommodate more than 1,000 employees.
- Combined lab operations will provide Exact Sciences the capacity to deliver more than 4.5 million Cologuard results per year.
Colon Cancer Awareness Month begins with PGA TOUR Champions event
The PGA TOUR and Exact Sciences (NASDAQ: EXAS), the manufacturer of Cologuard, announced today an agreement making the early cancer detection company title sponsor of the PGA TOUR Champions event in Tucson. The Cologuard Classic, named after Exact Sciences’ noninvasive at-home colon cancer screening test, will be contested the week of February 26-March 4, 2018 at Omni Tucson National’s Catalina Course, with a three-year agreement in place through the 2020 season. The Tucson Conquistadores will continue to operate the event.
#TeamCologuard tells the stories of Exact Sciences team members who work behind-the-scenes to complete your Cologuard test. Meet the people who are helping you get screened for colon cancer.
Quarterly test volume grew 136 percent to 161,000 completed tests
- Revenue guidance raised to $254-257 million for full-year 2017 from $230-240 million
- Guidance for Cologuard tests to be completed during 2017 increased to 568,000-572,000 tests from at least 550,000
- More than 10,000 additional providers ordered Cologuard for the first time during the third quarter
MADISON, Wis., Oct. 30, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $72.6 million and completed approximately 161,000 Cologuard tests during the quarter ended Sept. 30, 2017. Third-quarter 2017 revenue and completed Cologuard test volume grew 158 percent and 136 percent, respectively, from the same period of 2016.
MADISON, Wis., Oct. 18, 2017 /PRNewswire/ -- Exact Sciences, the manufacturer of Cologuard, announced today the four Grand Prize winners of the Green Bay Packers-Cologuard Colon Cancer Awareness Campaign. Each receives two bowl tickets to the Packers game at Lambeau Field on Sunday, October 22. Winning names were drawn from more than 1,300 entries.
The ticket winners are: Nicholas Pierson (Oshkosh, Wis.); Nathan Plitzuweit (Green Bay, Wis.); Stephanie Ronzio (Carlisle, Pa.); and Holly Setson (Smyrna, Ga.).
Pledging to help increase screening offers fans opportunity to win Packers tickets and prizes
GREEN BAY and MADISON, Wis. – Aug. 16, 2017 – The Green Bay Packers and Exact Sciences, the manufacturer of Cologuard, are teaming up to promote colorectal cancer awareness throughout the 2017 football season.
Colon cancer took the life of legendary Packers coach Vince Lombardi at age 57 and almost 50 years later remains the number two cancer killer in the United States, according to the U.S. Centers for Disease Control and Prevention.
Cologuard® revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests
- Revenue guidance raised to $230-240 million for 2017, from $195-205 million
- Guidance for Cologuard tests to be completed during 2017 increased to at least 550,000 tests, from at least 470,000
- 11,000 additional providers ordered Cologuard for the first time during the second quarter, and insurance coverage expanded to 86 percent of target population
MADISON, Wis., July 25, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $57.6 million and completed approximately 135,000 Cologuard tests during the quarter ended June 30, 2017. Second-quarter 2017 revenue and completed Cologuard test volume grew 172 percent and 149 percent from the same period of 2016, respectively.
Golfer launches multi-year, Cologuard®-branded campaign
MADISON, Wis., June 22, 2017 /PRNewswire/ -- Exact Sciences today announced it is teaming up with Madison professional golfer Jerry Kelly to help drive home the importance of colorectal cancer screening. Beginning at this week's American Family Insurance Championship, Kelly will wear a Cologuard-branded hat for the next two years at tournaments around the country to help raise awareness of colon cancer and the importance of regular screening beginning at age 50 for individuals at average risk.